The US company's full-stack R&D engine generates multifunctional T cell medicines, enabled by precise and specific CRISPR insertion of large synthetic DNA sequences. It is building the industry’s largest DNA library of therapeutic-enhancing integrated circuits, incorporating logic gating for improved tumor targeting and synthetic features enabling multiple pharmaceutical functions.

In September 2022, ArsenalBio closed a $220 million Series B financing which will help the company expand its programmable cell therapy research activities and grow its pipeline of therapeutic candidates for solid tumor malignancies across a range of cancer indications.